MedTrace Logo

Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer

NCT07396324 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2026-05-13

No results posted yet for this study

Summary

This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.

Conditions

  • HR-positive/HER2-negative Breast Cancer

Interventions

DRUG

Iparomlimab and Tuvonralimab

5.0mg/kg qw, start from C1D15

DRUG

Paclitaxel

80mg/m\^2 qw

DRUG

Carboplatin

AUC=1.5, D1, 8, 15, every 28 days

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Wenjin Yin · Renji Hospital, School of Medicine, Shanghai Jiaotong University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2026-12-31
Completion
2031-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07396324 on ClinicalTrials.gov